IL178495A - Use of cancerous gastric components or artificial calcium containing carbonate, chitin and polypeptide preparations to treat calcium metabolism-related or calcium-signaling conditions - Google Patents

Use of cancerous gastric components or artificial calcium containing carbonate, chitin and polypeptide preparations to treat calcium metabolism-related or calcium-signaling conditions

Info

Publication number
IL178495A
IL178495A IL178495A IL17849506A IL178495A IL 178495 A IL178495 A IL 178495A IL 178495 A IL178495 A IL 178495A IL 17849506 A IL17849506 A IL 17849506A IL 178495 A IL178495 A IL 178495A
Authority
IL
Israel
Prior art keywords
calcium
chitin
polypeptide
medicament
preparation
Prior art date
Application number
IL178495A
Other languages
English (en)
Hebrew (he)
Other versions
IL178495A0 (en
Inventor
Yosef Ben
Amir Sagi
Original Assignee
Univ Ben Gurion
Yosef Ben
Amir Sagi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ben Gurion, Yosef Ben, Amir Sagi filed Critical Univ Ben Gurion
Priority to IL178495A priority Critical patent/IL178495A/en
Publication of IL178495A0 publication Critical patent/IL178495A0/en
Priority to PT78271855T priority patent/PT2068891E/pt
Priority to DK07827185.5T priority patent/DK2068891T3/da
Priority to SI200731375T priority patent/SI2068891T1/sl
Priority to ES07827185.5T priority patent/ES2439741T3/es
Priority to PCT/IL2007/001211 priority patent/WO2008041236A2/en
Priority to EP07827185.5A priority patent/EP2068891B1/en
Priority to AU2007303786A priority patent/AU2007303786B2/en
Priority to CA2665141A priority patent/CA2665141C/en
Priority to CNA200780045195XA priority patent/CN101563091A/zh
Priority to JP2009531012A priority patent/JP2010505818A/ja
Priority to PL07827185T priority patent/PL2068891T3/pl
Priority to US12/443,987 priority patent/US20100098774A1/en
Priority to US13/728,508 priority patent/US8728533B2/en
Priority to CY20131101156T priority patent/CY1114930T1/el
Publication of IL178495A publication Critical patent/IL178495A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
IL178495A 2006-10-05 2006-10-05 Use of cancerous gastric components or artificial calcium containing carbonate, chitin and polypeptide preparations to treat calcium metabolism-related or calcium-signaling conditions IL178495A (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
IL178495A IL178495A (en) 2006-10-05 2006-10-05 Use of cancerous gastric components or artificial calcium containing carbonate, chitin and polypeptide preparations to treat calcium metabolism-related or calcium-signaling conditions
US12/443,987 US20100098774A1 (en) 2006-10-05 2007-10-07 Composition comprising crustacean gastrolith components and its use
EP07827185.5A EP2068891B1 (en) 2006-10-05 2007-10-07 Composition comprising crustacean gastrolith components, calcium carbonate and its use
CA2665141A CA2665141C (en) 2006-10-05 2007-10-07 Composition comprising crustacean gastrolith components and its use
SI200731375T SI2068891T1 (sl) 2006-10-05 2007-10-07 Sestavek, ki obsega gastrolitne komponente rakov, kalcijev karbonat, in njegova uporaba
ES07827185.5T ES2439741T3 (es) 2006-10-05 2007-10-07 Composición que comprende componentes de gastrolitos de crustáceos, carbonato cálcico y su utilización
PCT/IL2007/001211 WO2008041236A2 (en) 2006-10-05 2007-10-07 Composition comprising crustacean gastrolith components, calcium carbonate and its use
PT78271855T PT2068891E (pt) 2006-10-05 2007-10-07 Composição que compreende componentes de gastrólito de crustaceo, carbonato de cálcio e sua utilização
AU2007303786A AU2007303786B2 (en) 2006-10-05 2007-10-07 Composition comprising crustacean gastrolith components, calcium carbonate and its use
DK07827185.5T DK2068891T3 (da) 2006-10-05 2007-10-07 Sammensætning omfattende krebsdyr gastrolith komponenter, calciumcarbonat og anvendelse deraf
CNA200780045195XA CN101563091A (zh) 2006-10-05 2007-10-07 包含甲壳类动物胃石组分、碳酸钙的组合物及其用途
JP2009531012A JP2010505818A (ja) 2006-10-05 2007-10-07 甲殻類の胃石成分を含む組成物とその使用
PL07827185T PL2068891T3 (pl) 2006-10-05 2007-10-07 Kompozycja zawierająca składniki gastrolitów skorupiaków, węglan wapnia i jej zastosowanie
US13/728,508 US8728533B2 (en) 2006-10-05 2012-12-27 Composition comprising crustacean gastrolith components and its use
CY20131101156T CY1114930T1 (el) 2006-10-05 2013-12-20 Συνθεση που περιλαμβανει συστατικα γαστρολιθου καρκινοειδων, ανθρακικο ασβεστιο και η χρηση της

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL178495A IL178495A (en) 2006-10-05 2006-10-05 Use of cancerous gastric components or artificial calcium containing carbonate, chitin and polypeptide preparations to treat calcium metabolism-related or calcium-signaling conditions

Publications (2)

Publication Number Publication Date
IL178495A0 IL178495A0 (en) 2007-02-11
IL178495A true IL178495A (en) 2014-12-31

Family

ID=39153987

Family Applications (1)

Application Number Title Priority Date Filing Date
IL178495A IL178495A (en) 2006-10-05 2006-10-05 Use of cancerous gastric components or artificial calcium containing carbonate, chitin and polypeptide preparations to treat calcium metabolism-related or calcium-signaling conditions

Country Status (14)

Country Link
US (2) US20100098774A1 (https=)
EP (1) EP2068891B1 (https=)
JP (1) JP2010505818A (https=)
CN (1) CN101563091A (https=)
AU (1) AU2007303786B2 (https=)
CA (1) CA2665141C (https=)
CY (1) CY1114930T1 (https=)
DK (1) DK2068891T3 (https=)
ES (1) ES2439741T3 (https=)
IL (1) IL178495A (https=)
PL (1) PL2068891T3 (https=)
PT (1) PT2068891E (https=)
SI (1) SI2068891T1 (https=)
WO (1) WO2008041236A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257750B2 (en) * 1999-04-30 2012-09-04 Kibow Biotech, Inc. Calcium carbonate compositions for preventing or treating hyperphosphatemia
PL2211873T3 (pl) 2007-10-22 2013-01-31 Amorphical Ltd Stabilny amorficzny węglan wapnia wchodzący w skład fosforylowanych aminokwasów
EP2790710B1 (en) 2011-12-13 2020-08-26 Amorphical Ltd. Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders
WO2014024191A1 (en) 2012-08-07 2014-02-13 Amorphical Ltd. Method for producing stabilized amorphous calcium carbonate
JP2016507553A (ja) * 2013-02-11 2016-03-10 アモーフィカル リミテッド． 骨成長を促進する非晶質炭酸カルシウム
CN103417635B (zh) * 2013-08-15 2015-05-20 张荣惠 接骨药
EP3174409A4 (en) 2014-07-31 2018-01-17 Amorphical Ltd. Encapsulated amorphous calcium carbonate compositions
US12121538B2 (en) 2015-06-04 2024-10-22 Amorphical Ltd. Compositions of amorphous calcium carbonate for inhalation, sublingual or buccal administration
HK1253702A1 (zh) * 2015-06-04 2019-06-28 艾玛菲克有限公司 用聚磷酸/聚磷酸酯/聚磷酸盐或双膦酸/双膦酸酯/双膦酸盐稳定的无定形碳酸钙
AU2016374162A1 (en) * 2015-12-14 2018-04-19 Nestec S.A. Nutritional compositions and infant formulas to promote myelination in the brain
MY197734A (en) * 2015-12-14 2023-07-12 Nestle Sa Nutritional compositions and infant formula for promoting de novo myealination
US11478011B2 (en) 2015-12-14 2022-10-25 Societe Des Produits Nestle S.A. Nutritional compositions and infant formula for promoting de novo myealination
JP6873389B2 (ja) 2016-01-18 2021-05-19 アモーフィカル リミテッド． 神経学的、筋肉、および不妊の疾患または症状の治療のための安定化無定形炭酸カルシウム
ES3052833T3 (en) 2016-01-18 2026-01-15 Amorphical Ltd Stabilized amorphous calcium carbonate as a supplement for cell culture media
JP7152785B2 (ja) * 2016-10-25 2022-10-13 アモーフィカル リミテッド． 白血病治療のための非晶質炭酸カルシウム
IL289237B2 (en) 2019-07-23 2026-03-01 Amorphical Ltd Amorphous calcium carbonate for improving athletic performance

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237147A (en) 1974-01-04 1980-12-02 Monsanto Company Stabilized amorphous calcium carbonate
US4199496A (en) * 1974-09-05 1980-04-22 Johnson Edwin L Process for the recovery of chemicals from the shells of crustacea
US5886012A (en) * 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers
US20060165784A1 (en) * 1997-05-06 2006-07-27 Zhao Jin R Calcium supplement
US20030077604A1 (en) * 2000-10-27 2003-04-24 Yongming Sun Compositions and methods relating to breast specific genes and proteins
JP2002205947A (ja) * 2000-12-11 2002-07-23 Chafflose Corporation 水虫治療薬
EP1416916B1 (en) * 2001-08-16 2007-10-17 Cmp Therapeutics Limited Chitin microparticles and their medical uses
JP2004081739A (ja) * 2002-08-29 2004-03-18 Mitsuru Akashi ハイドロキシアパタイト−ポリマー複合材料の止血用組成物
WO2005025581A1 (fr) * 2003-09-17 2005-03-24 Third Military Medical University, Chinese People's Liberation Army, P.R. Of China Utilisation de la n-acetyl-d-aminoglycosamine pour la preparation de medicaments de traitement du cancer et des metastases
CA2567972C (en) * 2004-05-26 2015-07-28 Ben-Gurion University Of The Negev Research And Development Authority Orally-administrable compositions comprising stable amorphous calcium carbonate
WO2006043966A2 (en) * 2004-10-15 2006-04-27 University Of Tennessee Research Foundation Methods for inducing apoptosis in adipocytes

Also Published As

Publication number Publication date
CY1114930T1 (el) 2016-12-14
WO2008041236A3 (en) 2009-05-14
EP2068891A2 (en) 2009-06-17
ES2439741T3 (es) 2014-01-24
US20130122117A1 (en) 2013-05-16
CA2665141A1 (en) 2008-04-10
US20100098774A1 (en) 2010-04-22
AU2007303786A1 (en) 2008-04-10
IL178495A0 (en) 2007-02-11
DK2068891T3 (da) 2014-01-13
PL2068891T3 (pl) 2014-03-31
CA2665141C (en) 2015-03-24
EP2068891B1 (en) 2013-09-25
CN101563091A (zh) 2009-10-21
AU2007303786B2 (en) 2012-07-26
SI2068891T1 (sl) 2014-02-28
PT2068891E (pt) 2013-12-27
JP2010505818A (ja) 2010-02-25
WO2008041236A2 (en) 2008-04-10
US8728533B2 (en) 2014-05-20

Similar Documents

Publication Publication Date Title
IL178495A (en) Use of cancerous gastric components or artificial calcium containing carbonate, chitin and polypeptide preparations to treat calcium metabolism-related or calcium-signaling conditions
IL221795B (en) Use of a pharmaceutical preparation of methylnaltrexone or a salt thereof for the preparation of a medicine for the treatment of side effects of treatment with opiates
EP2671584A3 (en) Compositions and methods for treating disorders associated with salt or fluid retention
EP1991218A4 (en) USE OF CYCLOLIGNANS IN THE TREATMENT OF TYPE 2 DIABETES AND AS CONTRACEPTIVES
PL2601961T3 (pl) Kompozycje zawierające LAG-3 i terapeutyczne przeciwciała oraz ich zastosowania w leczeniu raka
IL197169A0 (en) Use of fgf-18 in the manufacture of a medicament for treatment of cartilage disorders
IL190284A (en) Use of milenzipran, or a suitable pharmaceutical salt, in the preparation of a drug for the treatment of fibromyalgia
IL196965A (en) Analogues of (r, r) or (s, r) phenoterol, their pharmaceutical composition containing them and their use for the treatment of heart failure
IL199265A (en) Oxindol derivatives are converted and used to make a drug
EP2079526A4 (en) COMPOSITIONS AND ITS USES IN THE TREATMENT OF WOUNDS
GB2443336B (en) Spiruchostatin analogues and their medicinal use
IL181445A0 (en) Use of (halobenzyloxy)benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium selective modulators
EP2099309A4 (en) COMPOSITION COMPRISING SUGAR AND SALT FOR THE TREATMENT OF MEAT
WO2009068708A8 (es) Composición farmacéutica de liberación sostenida de somatostatina o un análogo suyo
IL208463A (en) 2-Trotocyclic-Pirol compounds combined, pharmaceutical preparations containing them and their use in the prevention or treatment of diabetes or obesity
EP1877344A4 (en) BIOFILTER UNITS AND WATER TREATMENT PLANTS THEREWITH
GB0523576D0 (en) Drug composition and its use in therapy
PL2012805T3 (pl) Kompozycja lecznicza i jej zastosowanie
IL196561A (en) Use of sulphamides and glinides in potassium-sensitive potassium channels atp in the preparation of pharmaceuticals for the treatment of diabetes and / or neuropsychological diseases
EP2080783A4 (en) CALCIUM CARBONATE TREATED WITH A HARDENING MATERIAL
PL2026821T3 (pl) Binarne mieszaniny kwasu hialuronowego i ich zastosowanie terapeutyczne
EP2119436A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF EYE DISEASES
GB2453671B (en) Preparation for use in the treatment of Clostridium difficile and Salmonella
PL2193789T3 (pl) Zastosowanie 5-metylo-1,3-benzenodiolu lub jego pochodnych w przygotowaniu leku i funkcjonalnej żywności do leczenia lub zapobiegania depresji
PL2640364T3 (pl) Kompozycja farmaceutyczna zawierająca sól wodorowęglanową i jej zastosowanie jako leku w leczeniu i/lub profilaktyce kamicy moczowej i chorób pokrewnych

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed